Latest news with #WELLHealthTechnologies
National Post
28-07-2025
- Business
- National Post
WELL Health to Announce Second Quarter 2025 Financial Results on August 14, 2025
Article content VANCOUVER, British Columbia — WELL Health Technologies Corp. (TSX: WELL) (OTCQX: WHTCF) ('WELL' or the 'Company'), a digital healthcare company focused on positively impacting health outcomes by leveraging technology to empower healthcare practitioners and their patients globally, is pleased to announce that the Company will release its Fiscal Second Quarter 2025 financial results for the period ended June 30, 2025, before the market opens on Thursday, August 14, 2025. The Company will hold a conference call and simultaneous webcast to discuss its results on the same day at 1:00 pm ET (10:00 am PT). The call will be hosted by Hamed Shahbazi, Chairman and Chief Executive Officer and Eva Fong, Chief Financial Officer. Please dial in 10 minutes prior to the start of the call. Article content Conference Call Participant Details Article content Date: Thursday, August 14, 2025 Article content Time: 1:00 PM ET / 10:00 AM PT Article content International Toll: 289-514-5100 Article content North American Toll Free: 1-800-717-1738 Article content To attend the webcast, register now or visit for details. Article content WELL HEALTH TECHNOLOGIES CORP. Article content Per: 'Hamed Shahbazi' Hamed Shahbazi Chief Executive Officer, Chairman and Director WELL Health Technologies Corp. Article content About WELL Health Technologies Corp. Article content WELL's mission is to tech-enable healthcare providers. We do this by developing the best technologies, services, and support available, which ensures healthcare providers are empowered to positively impact patient outcomes. WELL's comprehensive healthcare and digital platform includes extensive front and back-office management software applications that help physicians run and secure their practices. WELL's solutions enable more than 42,000 healthcare providers between the US and Canada and power the largest owned and operated healthcare ecosystem in Canada with more than 210 clinics supporting primary care, specialized care, and diagnostic services. In the United States, WELL's solutions are focused on specialized markets such as the gastrointestinal market, women's health, primary care, and mental health. WELL is publicly traded on the Toronto Stock Exchange under the symbol 'WELL' and on the OTC Exchange under the symbol 'WHTCF'. To learn more about the Company, please visit: Article content Article content Article content Article content Contacts Article content Article content Article content Article content
National Post
15-07-2025
- Business
- National Post
WELL Health Subsidiary WELLSTAR Provides Corporate Update Reflecting Improved Guidance and a Strong Acquisition Pipeline
Article content WELLSTAR continues to demonstrate strong growth and business momentum through its sustained organic growth and strong acquisition pipeline. The business is ahead of its internal expectations and has updated its guidance to $74 million (1) in total revenue and $22 million (1) in Adjusted EBITDA (2) for fiscal 2025, ending the year with total ARR of $62 million and an exit ARR (3) of approximately $80 million. WELLSTAR has executed three LOIs for acquisitions that will drive approximately $15 million in ARR, $16 million in revenues and over $5 million in Adjusted EBITDA on an annualized basis. WELLSTAR's recently launched Nexus AI™ solution has generated significant early momentum. As a pre-qualified vendor for Canada Health Infoway's AI Scribe Program, eligible primary care clinicians can now receive a fully-funded Nexus AI license for 12 months. Article content VANCOUVER, British Columbia & TORONTO — WELL Health Technologies Corp. (TSX: WELL) (' WELL ' or the ' Company '), a company focused on positively impacting health outcomes by leveraging technology to empower healthcare providers and their patients, is pleased to provide a corporate update highlighting continued momentum across its majority-owned subsidiary, WELLSTAR Technologies Corp. (' WELLSTAR '). WELLSTAR is tracking ahead of internal expectations, supported by robust organic growth, a strong acquisition pipeline, and accelerating adoption of its Nexus AI solution. Article content WELLSTAR continues to demonstrate strong growth and execution, fueled by accelerating demand for its digital health solutions and steady progress across its platform. The business is tracking ahead of internal expectations and has updated its guidance for fiscal 2025 to over $74 million (1) in revenue and $22 million (1) in Adjusted EBITDA (2). WELLSTAR is also expected to end the year with total annual recurring revenue (ARR) of approximately $62 million and an exit ARR (3) of approximately $80 million, supported by robust organic expansion, continued adoption of its AI-powered tools, and inclusive of completing three acquisitions that are currently in signed LOI stage. Article content Amir Javidan, CEO of WELLSTAR commented, 'We've had an excellent first half to 2025 as both our organic and inorganic growth engines are levelling up and are poised to deliver an outstanding, breakout performance for WELLSTAR in 2025. At the beginning of the year, we set an ambitious goal of reaching $100M in revenues on a run-rate basis in the next couple of years and based on the latest forecasts, we believe we may be approaching that goal a few quarters earlier than previously anticipated. Our current goal for year-end exit ARR for fiscal 2025 is $80 million which would represent a 50% increase over last year's exit ARR figure. Article content Darren Hoegler, CFO of WELLSTAR commented, 'This upward revision reflects stronger-than-expected traction across WELLSTAR's core product suite as well as strong execution in the company's capital allocation program. We currently have three signed LOIs with targets that all deliver high-margin SaaS solutions and would be highly accretive to our business. I'm also pleased to report that the two acquisitions that were completed in Q4 2024 are both operating well and tracking in alignment with or ahead of our plan. Our objective is to ensure disciplined execution and that the company continues to be positioned as a category leader in Canadian digital health, delivering durable, capital-efficient growth with significant operating leverage over time.' Article content Three LOIs Executed as WELLSTAR Executes on Deep Acquisition Pipeline Article content WELLSTAR has executed three letters of intent (LOIs) for acquisitions that are expected to contribute approximately $15 million in ARR, $16 million in revenue, and over $5 million in Adjusted EBITDA on an annualized run-rate basis. These prospective additions reflect WELLSTAR's continued focus on disciplined, accretive growth through the acquisition of complementary digital health assets that strengthen its core platform and expand its national footprint. Article content The acquisitions are aligned with WELLSTAR's long-term strategy to build a technology-enabled healthcare infrastructure that is efficient, scalable, and outcomes-driven. Each target adds strategic value by extending WELLSTAR's clinician enablement capabilities. The integrated nature of WELLSTAR's platform enables smooth onboarding and operational alignment, allowing new assets to benefit from shared infrastructure and drive incremental impact across the broader business. Article content WELLSTAR continues to advance a deep and well-qualified acquisition pipeline, with additional opportunities under review. Article content Strong Early Traction for Nexus AI with Clinicians Nationwide Article content Since its launch on May 7, 2025, Nexus AI has seen strong adoption, with over 2,400 providers signed up across primary care clinics, hospitals, and regional health authorities. Nexus AI's first feature, an ambient medical scribe for real-time clinical documentation, is already demonstrating meaningful value for providers by reducing administrative burden and cognitive load. AI medical scribe technology has been shown to save providers up to two hours per day in charting and documentation (4). Article content Nexus AI serves as the central platform for WELLSTAR's expanding suite of AI-powered capabilities, including disease detection, medical coding and billing automation, and clinical decision support. Its compatibility with Canada's leading EMRs positions it as a scalable infrastructure layer for modern, intelligent healthcare delivery. Article content Clinician engagement with Nexus AI is expected to contribute to WELLSTAR's recurring SaaS revenue and margin profile as deployments scale. Just as importantly, the platform's ability to orchestrate complex clinical workflows in an intuitive and context-aware way supports broader system-level efficiency and provider satisfaction. As a pre-qualified vendor of the Canada Health Infoway AI Scribe Program, eligible primary care clinicians across Canada will receive a fully-funded license for 12 months of Nexus AI. WELLSTAR recognizes this as a transformative opportunity to advance Canada's vision of connected care, where AI-enabled technologies reduce physician burnout, improve patient experience, and allow providers to focus more on engagement and less on documentation. By delivering accurate, secure documentation at the point of care, Nexus AI empowers providers to reclaim meaningful patient connections and supports a broader effort to integrate AI technologies that promote more connected, patient-centred care. Footnotes: Article content WELLSTAR's guidance of $74 million in revenue and $22 million in Adjusted EBITDA in fiscal 2025 includes the impact from the three LOIs noted herein which will contribute approximately $4 million in revenue and $1 million in Adjusted EBITDA for inclusion in fiscal 2025. Note that this figure does not include certain shared services that are provided by WELL Health to WELLSTAR. Adjusted EBITDA is a non-GAAP financial measure. Please refer to WELL's most recent Management's Discussion and Analysis (MD&A), available under the Company's profile on SEDAR+ at for further details including definitions and reconciliations to the nearest IFRS measure. Exit ARR or Annual Recurring Revenue is based on the Company's revenue run-rate or ARR as annualized based on the last quarter of the year. The projected Exit ARR of approximately $80 million includes contribution from the three LOIs noted herein. Source: OntarioMD, AI scribes show promising results in helping family doctors and nurse practitioners spend more time with patients and less time on paperwork, September 11, 2024. Article content WELL HEALTH TECHNOLOGIES CORP. Article content Per: 'Hamed Shahbazi' Article content Hamed Shahbazi Article content Chief Executive Officer, Chairman and Director Article content About WELL Health Technologies Corp. Article content WELL's mission is to tech-enable healthcare providers. We do this by developing the best technologies, services, and support available, which ensures healthcare providers are empowered to positively impact patient outcomes. WELL's comprehensive healthcare and digital platform includes extensive front and back-office management software applications that help physicians run and secure their practices. WELL's solutions enable more than 42,000 healthcare providers between the US and Canada and power the largest owned and operated healthcare ecosystem in Canada with more than 210 clinics supporting primary care, specialized care, and diagnostic services. In the United States, WELL's solutions are focused on specialized markets such as the gastrointestinal market, women's health, primary care, and mental health. WELL is publicly traded on the Toronto Stock Exchange under the symbol 'WELL' and on the OTC Exchange under the symbol 'WHTCF'. To learn more about the Company, please visit: Article content Forward-Looking Statements Article content Certain statements in this press release, constitute 'forward-looking information' and 'forward looking statements' (collectively, 'forward looking statements') within the meaning of applicable Canadian securities laws, including the guidance related to revenue and adjusted EBITDA, and the expected pipeline of future acquisition targets (and the associated run-rate revenue). Forward-looking statements are necessarily based upon management's expectations, while considered reasonable by WELL as of the date of such statements, are outside of WELL's control and are inherently subject to business, economic and other uncertainties and contingencies which could result in the forward-looking statements ultimately being entirely or partially incorrect or untrue. Forward looking statements contained in this press release are based on various assumptions, including, but not limited to the ability to continue to offer its products and services, complete the acquisitions, and the acquisition companies having the expected revenue and Adjusted EBITDA profiles based on WELL's diligence. Article content Known and unknown risk factors, many of which are beyond the control of WELL could cause the actual plans to differ materially from the results implied by such forward-looking statements. Such risk factors include losing customers to competitors, cybersecurity threats which prevent WELLSTAR from being able to continually offer its products, not completing the three acquisitions discussed above, and the other risks discussed under the section entitled 'Risk Factors' in WELL's most recent annual information form, which is available under the Company's respective SEDAR+ profile at which could affect WELL's and WELLSTAR's business. The risk factors are not intended to represent a complete list of the factors that could affect WELL or WELLSTAR and the reader is cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking statements. There can be no assurance that forward looking statements will prove to be accurate. Forward-looking statements are provided for the purpose of providing information about management's expectations and plans relating to the future. WELL disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, or to explain any material difference between subsequent actual events and such forward-looking statements, except to the extent required by applicable law. All of the forward-looking statements contained in this press release are qualified by these cautionary statements. Article content Article content Article content Article content Contacts Article content For more information: Article content Article content Tyler Baba Article content Article content Article content
Yahoo
16-06-2025
- Health
- Yahoo
Abstractive Health introduces new AI simulation for diagnostic training
Abstractive Health has introduced an AI-driven simulation known as Clinical Time Machine, designed to enhance diagnostic training for physicians. Currently accessible via Abstractive Health's platform, the clinical solution allows medical professionals to engage with real historical medical cases, providing a risk-free environment for exploring rare and complex conditions. Developed on a HIPAA-compliant platform that also facilitates the real-time summarisation of electronic health records (EHRs) in hospitals, Clinical Time Machine allows clinicians to delve into diagnostic cases from the past. The solution does not require any direct EHR integration. Abstractive Health CEO Vince Hartman said: 'Three years after ChatGPT, fewer than 1% of physicians have ever seen an AI full medical record summary. We're changing that.' Each simulation begins with an AI-generated summary of original medical documents, some dating back hundreds of years. Clinicians navigate through a structured chart, examining everything from the history of the current illness to laboratory results and vital signs. They obtain simulated updates that reflect clinical observations made at the time. Hartman added: 'It's not a quiz. It's about engaging clinical reasoning in a sandbox where doctors can make decisions and learn from them.' The technology behind Clinical Time Machine is based on Abstractive Health's summarisation, retrieval-augmented generation (RAG), and agentic AI platform. It utilises advanced optical character recognition (OCR) and an AI summarisation pipeline capable of transforming handwritten notes into coherent clinical narratives. Currently, the summarisation solution is being trialled at Weill Cornell Medicine in a research partnership aimed at improving Emergency Medicine handoff notes. Furthermore, Abstractive Health is set to expand the simulation's reach to outpatient clinics in Canada through a collaboration with WELL Health Technologies, which was established after an investment and distribution agreement last year. "Abstractive Health introduces new AI simulation for diagnostic training" was originally created and published by Hospital Management, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
14-05-2025
- Business
- Yahoo
WELL Health Technologies (TSX:WELL) Reports CAD 46M Loss Despite 32% Revenue Growth
WELL Health Technologies reported a significant increase in Q1 2025 sales, though they also transitioned from a profit to a notable net loss. Over the past week, the company's stock rose 8.55%, a movement worth noting amidst a broader market rally of 5.3%. While WELL Health's substantial sales growth might have contributed positively, the net loss may have tempered excitement. Despite this, broader market trends led by tech sector gains, such as those in Nvidia and AMD, might have further buoyed investor sentiment towards WELL Health, aligning its performance with the general uptrend in the market. We've discovered 1 risk for WELL Health Technologies that you should be aware of before investing here. Outshine the giants: these 30 early-stage AI stocks could fund your retirement. The recent news surrounding WELL Health Technologies' transition from profit to a net loss, despite a reported increase in sales, could have implications for its future revenue and earnings trajectory. Although the stock rose 8.55% over the past week, aligning with a broader market rally, the company's five-year total shareholder return was 37.38%. This long-term performance offers a more tempered view compared to the single-year performance, where WELL Health underperformed the Canadian Healthcare industry, which returned 33%. In light of the recent developments, analysts' revenue growth projections for WELL Health could be influenced by the integration challenges of acquisitions and the impact of deferred revenues. With anticipated earnings of CA$47.4 million by 2028, there is pressure to enhance operational efficiencies to meet these expectations. Furthermore, the price movement towards the analyst consensus price target of CA$7.86, which stands at a notable premium over the current share price of CA$3.98, reflects investor optimism. Yet, this also highlights the need for the company to achieve substantial growth in both revenue and earnings to justify such a valuation. The announced initiatives, including strategic divestments and an anticipated IPO, could play a crucial role in altering WELL Health's financial landscape in the coming years. Navigate through the intricacies of WELL Health Technologies with our comprehensive balance sheet health report here. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include TSX:WELL. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
11-05-2025
- Business
- Yahoo
1 Magnificent Healthcare Stock Down 46% to Buy and Hold Forever
Written by Adam Othman at The Motley Fool Canada Global stock markets have been incredibly volatile for several months, leaving plenty of new investors unsure of where to get the best returns with their capital right now. If you can look past the challenges of short-term market volatility and embrace a long-term view, there are plenty of high-quality opportunities waiting for your investment capital. The global landscape is changing across every sector of the economy, especially with the sudden rise in artificial intelligence (AI) technology advancements and adoption. AI is making improvements in every space, including the healthcare sector. The profound shift in healthcare technology, enabled by years of innovation and accelerated with AI technology, presents new and exciting growth opportunities for investors who can identify them. One such tech stock in the healthcare sector is WELL Health Technologies (TSX:WELL). The $983.91 million market-cap company is one of the businesses leading the charge in healthcare innovation, and it trades at a considerable discount from its all-time highs. Let's take a better look at the stock to see why it might be an excellent holding to add to your self-directed investment portfolio. WELL Health used to be a telehealth company that came into the limelight a few years ago during the pandemic. Social-distancing restrictions and health scares forced telemedicine adoption to speed up much faster than anticipated. Business boomed for WELL Health, as it provided better access to healthcare services to patients when they needed it the most from the safety of their homes. The company used the momentum well and made a series of aggressive acquisitions that have made it a comprehensive digital healthcare company. It is now Canada's largest owner and operator of outpatient health clinics, delivering healthcare-related services across Canada and the U.S. More recently, the company has started integrating AI technology into its range of services to improve the quality of patient care while streamlining operational efficiencies for healthcare providers. One of the best examples of its AI-powered innovations is WELL AI Voice, an assistant for healthcare providers that offers clinical documentation through natural language processing and voice recognition. Its WELL AI Decision Support offers important insights and recommendations to healthcare professionals by analyzing vast sets of patient data to help them make more efficient treatment plans and accurate diagnoses. Despite the decline in the need for telehealth services in the post-pandemic era, WELL Health is doing well as a business. The company had strong financials in fiscal 2024, reporting a 19% year-over-year growth in annual revenue, an almost 75% increase in net income, and a 16.3% uptick in free cash flow attributable to its investors. Looking ahead, the company has a positive outlook for fiscal 2025, with its projected revenue expected to be as high as $1.5 billion. As of this writing, WELL Health stock trades for $3.95 per share, down by over 46% from its 52-week high. If you are interested in investing in a high-growth space and have a well-balanced portfolio to help you ride the wave of any short-term market volatility, WELL Health stock can be an excellent pick to consider. The post 1 Magnificent Healthcare Stock Down 46% to Buy and Hold Forever appeared first on The Motley Fool Canada. Before you buy stock in WELL Health Technologies, consider this: The Motley Fool Stock Advisor Canada analyst team just identified what they believe are the Top Stocks for 2025 and Beyond for investors to buy now… and WELL Health Technologies wasn't one of them. The Top Stocks that made the cut could potentially produce monster returns in the coming years. Consider MercadoLibre, which we first recommended on January 8, 2014 ... if you invested $1,000 in the 'eBay of Latin America' at the time of our recommendation, you'd have $21,345.77!* Stock Advisor Canada provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month – one from Canada and one from the U.S. The Stock Advisor Canada service has outperformed the return of S&P/TSX Composite Index by 24 percentage points since 2013*. See the Top Stocks * Returns as of 4/21/25 More reading Made in Canada: 5 Homegrown Stocks Ready for the 'Buy Local' Revolution [PREMIUM PICKS] Market Volatility Toolkit Best Canadian Stocks to Buy in 2025 Beginner Investors: 4 Top Canadian Stocks to Buy for 2025 5 Years From Now, You'll Probably Wish You Grabbed These Stocks Subscribe to Motley Fool Canada on YouTube Fool contributor Adam Othman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. 2025 Sign in to access your portfolio
